Tirzepatide reduces albuminuria in patients with type 2 diabetes: post-hoc pooled analysis of SURPASS 1-5

被引：0
|
作者：
Wiese, R. J. [1 ]
Heerspink, H. J. L. [2 ]
Tuttle, K. R. [3 ]
Pavo, I. [1 ]
Haupt, A. [1 ]
Yang, Z. [1 ]
Hemmingway, A. [1 ]
Cherney, D. Z. I. [4 ]
Sattar, N. [5 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
[3] Univ Washington, Providence Hlth Care, Spokane, WA USA
[4] Univ Toronto, Univ Hlth Network, Toronto Gen Hosp, Div Nephrol,Dept Med, Toronto, ON, Canada
[5] Univ Glasgow, Glasgow, Lanark, Scotland
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [31] Effect of Tirzepatide on Kidney Function in People with Excess Body Weight and Type 2 Diabetes-A Post-Hoc Analysis of the SURMOUNT-2 Trial
    Heerspink, Hiddo L.
    Friedman, Allon
    Bjornstad, Petter
    Van Raalte, Daniel
    Cao, Dachuang
    Garcia-Perez, Luis-Emilio
    Stefanski, Adam
    Turfanda, Ibrahim
    Bunck, Mathijs C.
    Benabbad, Imane
    De Oliveira, Carolina Piras
    Griffin, Ryan
    DIABETES, 2024, 73
  • [32] Sitagliptin reduces albuminuria in patients with type 2 diabetes
    Hattori, Sachiko
    ENDOCRINE JOURNAL, 2011, 58 (01) : 69 - 73
  • [33] Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes
    Ferreira, Joao Pedro
    Sharma, Abhinav
    Vasques-Novoa, Francisco
    Angelico-Goncalves, Antonio
    Leite, Ana Rita
    Borges-Canha, Marta
    Carvalho, Davide
    Packer, Milton
    Zannad, Faiez
    Leite-Moreira, Adelino
    Neves, Joao Sergio
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (10) : 1792 - 1801
  • [34] Lixisenatide and Renal Outcomes in Patients with Type 2 Diabetes-A Post-Hoc Analysis of the ELIXA Trial
    Muskiet, Marcel A.
    Tonneijck, Lennart
    Huang, Yao
    Liu, Minzhi
    Saremi, Aramesh
    Heerspink, Hiddo Lambers.
    Van Raalte, Daniel H.
    DIABETES, 2018, 67
  • [35] Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data
    Jaime A. Davidson
    William Stager
    Sachin Paranjape
    Rachele Berria
    Lawrence A. Leiter
    Clinical Diabetes and Endocrinology, 6 (1):
  • [36] Changes in Lipid Concentrations in Patients with Type 2 Diabetes on Once-Weekly Dulaglutide 1.5 mg: Post-hoc Pooled Analysis of the AWARD Trials
    Sattar, Naveed A.
    Garcia-Perez, Luis E.
    Tao, Yebin
    Thieu, Vivian T.
    Pavo, Imre
    DIABETES, 2017, 66 : A288 - A289
  • [37] Patient-reported outcomes in patients with type 2 diabetes treated with tirzepatide or placebo (SURPASS-1)
    Boye, K.
    Yu, M.
    Lee, C. J.
    Mao, H.
    Cui, X.
    Lando, L. Fernandez
    Thieu, V.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 246 - 247
  • [38] Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups
    Bi, Yan
    Lu, Song
    Tang, Jiani
    Du, Liying
    Ji, Linong
    DIABETES THERAPY, 2024, 15 (05) : 1125 - 1137
  • [39] Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups
    Yan Bi
    Song Lu
    Jiani Tang
    Liying Du
    Linong Ji
    Diabetes Therapy, 2024, 15 : 1125 - 1137
  • [40] Cardiovascular outcomes in patients with type 2 diabetes and reduced eGFR and albuminuria: a REWIND post hoc subgroup analysis
    Colhoun, H.
    Malik, R.
    Botros, F.
    Atisso, C.
    Gerstein, H.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S282 - S282
12345